QHSLab, Inc.
QHSLab is a digital health company that helps independent, physician-led primary care practices identify, document and manage behavioral health conditions through digital screening and follow-up care. Its QHSLab platform provides digital assessments, automated reports delivered to practices’ electronic health records, patient education and ongoing digital engagement. Practices pay recurring per-patient, per-month fees for platform access and related services; QHSLab does not bill patients or payers directly. The company also offers allergy screening, diagnostics and treatment services under its AllergiEnd® brand. Its products include disposable, single-use allergy skin test applicators and matching test trays, along with training and operational support for participating practices. Physicians may prescribe immunotherapy, with preparations supplied by third-party compounding pharmacies. QHSLab’s target customers are generally independent practices with one to ten providers. It is headquartered in West Palm Beach, Florida.
No enriched coverage for $USAQ in the last 7 days.
No SEC Form 4 filings for $USAQ in the last 30 days.
See all $USAQ insider activity →QHSLab reported 3Q 2026 revenue of $677.17K, down 8.1% YoY. Integrated Service Program revenue grew 17.4%, while allergy products revenue fell 37.0%. Net income turned to a loss of $53.15K. Gross margin rose to 69.2%, and operating expenses increased due to higher marketing and payroll costs.
QHSLab reported 3Q 2026 revenue of $677.17K, down 8.1% YoY. Integrated Service Program revenue grew 17.4%, while allergy products revenue fell 37.0%. Net income turned to a loss of $53.15K. Gross margin rose to 69.2%, and operating expenses increased due to higher marketing and payroll costs.
AlphAI scores every news story that mentions USAQ with an AI model for sentiment and relevance, and aggregates insider trades from QHSLab, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
QHSLab reported 3Q 2026 revenue of $677.17K, down 8.1% YoY. Integrated Service Program revenue grew 17.4%, while allergy products revenue fell 37.0%. Net income turned to a loss of $53.15K. Gross margin rose to 69.2%, and operating expenses increased due to higher marketing and payroll costs.
